Read by QxMD icon Read


Yasmeen Jabeen Bhat, Iffat Hassan, Peerzada Sajad, Atiya Yaseen, Syed Mubashir, Saniya Akhter, Roohi Wani
BACKGROUND: Epidermal naevi are benign hamartomatous growths of the skin which are generally asymptomatic with a benign course but are cosmetically disagreeable. Topical treatments such as steroids, calcipotriol, 5 fluorouracil, podophyllin, retinoids and cryotherapy are ineffective and surgical excision results in scar formation. Therapy is often challenging. AIM OF THE STUDY: To study the response of carbon dioxide (CO2) laser in the management of epidermal naevi...
July 2016: Journal of Cutaneous and Aesthetic Surgery
J-H Lee, C-J Park, T-Y Kim, Y-B Choe, N-I Kim, H-J Song, J-I Youn, S-W Youn, J-H Choi, K-J Kim
BACKGROUND: There is a lack of response data for topical treatments for psoriasis vulgaris in Asian patients. OBJECTIVES: To determine the optimal maintenance regimen for topical treatment with calcipotriol monohydrate/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris, by comparing the efficacy of three 8-week maintenance regimens. METHODS: This was a multicentre, prospective, randomized, controlled, parallel-group, open-label, phase 4 clinical trial, conducted in South Korea...
October 10, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Liming Lu, Meiling Xuan, Yuhong Yan, Geng Li, Li Zhou, Zehuai Wen, Chuanjian Lu
BACKGROUND: Psoriasis vulgaris (PV) has been causing increasing concern due to its highly prevalent, harmful and therapy-resistant characteristics. The YXBCM01 (Chinese herbal medicine) for PV trial evaluates the effects of YXBCM01 on relapse rate in patients suffering from PV. As an update to the published design and method for the trial, this paper presents the statistical plan for the main publication to avoid the risk of outcome reporting bias, selective reporting, and data-driven results...
October 3, 2016: Trials
Linda Stein Gold, John Villumsen, Monika Rosen
INTRODUCTION: Good treatment adherence is important in the effective management of psoriasis and is related to both the frequency of applications and the amount of product used versus the recommended dose. The efficacy and safety of fixed combination calcipotriol 50 µg/g (Cal) and betamethasone 0.5 mg/g as dipropionate (BD) in the treatment of psoriasis is well established; an aerosol foam formulation has been developed to enhance adherence. This subanalysis from the Phase III PSO-FAST study evaluates the amount of Cal/BD foam used during treatment and the association between the extent and severity of baseline disease...
October 6, 2016: Dermatology and Therapy
Esther S Kim, James E Frampton
Calcipotriol/betamethasone dipropionate foam (Enstilar(®)) is a once-daily synthetic vitamin D3 analogue and synthetic corticosteroid fixed-dose combination foam formulation that is indicated for the topical treatment of plaque psoriasis in adults. In randomized, multicentre trials, treatment with calcipotriol/betamethasone dipropionate foam for 4 weeks resulted in greater proportions of patients achieving treatment success [of the body (i.e. trunk and/or limbs), as assessed by a physician] compared with 4 weeks' treatment with the foam vehicle, individual components as foam, or calcipotriol/betamethasone dipropionate fixed-dose combination as an ointment, or 8 weeks' treatment with the fixed-dose combination as a topical suspension...
October 2016: Drugs
M Nasimi, R Abedini, A Azizpour, A Nikoo
Linear psoriasis (LPs) is considered a rare clinical presentation of psoriasis, which is characterized by linear erythematous and scaly lesions along the lines of Blaschko. We report the case of a 20-year-old man who presented with asymptomatic linear and S-shaped erythematous, scaly plaques on right side of his trunk. The plaques were arranged along the lines of Blaschko with a sharp demarcation at the midline. Histological examination of a skin biopsy confirmed the diagnosis of psoriasis. Topical calcipotriol and betamethasone dipropionate ointments were prescribed for 2 months...
October 2016: Clinical and Experimental Dermatology
Ting-Shun Wang, Tsen-Fang Tsai
BACKGROUND: Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it. OBJECTIVE: Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely. METHODS: Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature...
September 21, 2016: American Journal of Clinical Dermatology
B Dyring-Andersen
No abstract text is available yet for this article.
August 2016: British Journal of Dermatology
C Paul, L Stein Gold, F Cambazard, R E Kalb, D Lowson, B Bang, C E M Griffiths
BACKGROUND: Fixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis. METHODS: The randomized, parallel-group, investigator-blinded Phase III, 12-week PSO-ABLE study compared the efficacy and safety of Cal/BD foam with Cal/BD gel. Patients aged ≥18 years with mild-to-severe psoriasis were randomized 4:4:1:1 to once-daily Cal/BD foam, Cal/BD gel, foam vehicle or gel vehicle (NCT02132936)...
August 17, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
Eman Wahsh, Nashwa Abu-Elsaad, Amr El-Karef, Tarek Ibrahim
Vitamin D was found to be involved in liver fibrosis modulation through binding to its receptor (VDR) halting many fibrotic pathways. Targeting vitamin D-VDR axis using vitamin D analogs may represent an efficient strategy for liver fibrosis treatment . The study aims at testing the potential ability of the VDR agonist, calcipotriol, to stop fibrosis progression and/or regeneration of hepatocytes in an experimental model of liver fibrosis. Mice (CD-1) were injected with thioacetamide (TAA, 100mg/kg, i.p., 3 times/week) for 8 weeks to induce fibrosis and were treated with calcipotriol (20, 60 or 80µg/kg, i...
October 15, 2016: European Journal of Pharmacology
Georgi Tchernev, Anastasiya Atanasova Chokoeva, Bogdana Ivanova, Hristo Mangarov, Nadezhda Georgieva Vidolova
Porokeratosis is defined as a disorder of keratinization characterized by one or more atrophic patches surrounded by a clinically and histologically distinctive hyperkeratotic ridgelike border called the cornoid lamella. Lesions are most commonly located on the sun-exposed sides of trunk and extremities, while exclusive facial involvement has been also reported. Despite that the exact risk of cutaneous malignancy developing in porokeratosis is unknown, it is confirmed by series of case reports, including squamous cell carcinoma, basal cell carcinoma and even melanoma...
July 28, 2016: Wiener Medizinische Wochenschrift
Ze-Huai Wen, Mei-Ling Xuan, Yu-Hong Yan, Xiao-Yan Li, Dan-Ni Yao, Geng Li, Xin-Feng Guo, Ai-Hua Ou, Chuan-Jian Lu
No abstract text is available yet for this article.
2016: Trials
Chen Dong, Charlotte Virtucio, Olga Zemska, Grober Baltazar, Yasheen Zhou, Diogo Baia, Shannon Jones-Iatauro, Holly Sexton, Shamra Martin, Joshua Dee, Yvonne Mak, Maliwan Meewan, Fernando Rock, Tsutomu Akama, Kurt Jarnagin
Psoriasis and atopic dermatitis are skin diseases affecting millions of patients. Here, we characterize benzoxaborole phosphodiesterase (PDE)-4 inhibitors, a new topical class that has demonstrated therapeutic benefit for psoriasis and atopic dermatitis in phase 2 or phase 3 studies. Crisaborole [AN2728, 4-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile], compd2 [2-ethoxy-6-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)nicotinonitrile], compd3 [6-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)-2-(2-isopropoxyethoxy)nicotinonitrile], and compd4 [5-chloro-6-((1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)-2-((4-oxopentyl)oxy)nicotinonitrile] are potent PDE4 inhibitors with similar affinity for PDE4 isoforms and equivalent inhibition on the catalytic domain and the full-length enzyme...
September 2016: Journal of Pharmacology and Experimental Therapeutics
Takahiro Suzuki, Kazuki Tatsuno, Taisuke Ito, Jun-Ichi Sakabe, Atsuko Funakoshi, Yoshiki Tokura
BACKGROUND: In relation to Th17 cell actions, interferon (IFN)-α production by plasmacytoid dendritic cells (pDCs) are involved in the pathogenesis of psoriasis. Vitamin D3 analogues are widely used in the treatment of psoriasis, however, their actions on pDCs are not well understood. OBJECTIVE: To investigate the effects of Vitamin D3 analogue calcipotriol (CAL) on pDCs, focusing on the cytokine production and chemotactic activity. METHODS: We compared in mice the effects of CAL, cyclosporine A (CyA), and triamcinolone acetonide (TA) on the cytokine production by pDCs (IFN-α), conventional DCs (TNF-α), and γd T cells (IL-17A)...
June 3, 2016: Journal of Dermatological Science
Atsushi Hosomi, Maho Hirabe, Takuya Tokuda, Hiroaki Nakamura, Toru Amano, Tadao Okamoto
Topical agents containing vitamin D3 (VD3) analogues such as calcipotriol, maxacalcitol and tacalcitol and the combination of calcipotriol/betamethasone dipropionate (betamethasone) are prescribed for patients with psoriasis. However, they are known to occasionally cause hypercalcemia, and the frequency of hypercalcemia is suggested to vary according to the VD3 analogue used. In this study, to address the reason for these differences, the calcemic effects of maxacalcitol-, calcipotriol- and calcipotriol/betamethasone-containing ointments in rats were evaluated...
October 5, 2016: European Journal of Pharmacology
Toshiharu Fujiyama, Taisuke Ito, Takatsune Umayahara, Shigeki Ikeya, Kazuki Tatsuno, Atsuko Funakoshi, Hideo Hashizume, Yoshiki Tokura
BACKGROUND: Topical combination of a vitamin D3 analogue and corticosteroid is widely used for the treatment of psoriasis, a TH17-mediated disorder, but the underlying mechanism remains unclear. OBJECTIVE: We investigated the effect of this topical applicant, focusing on skin-infiltrating TH17 cells. METHODS: In 10 patients with plaque psoriasis, calcipotriol (Cal), betamethasone dipropionate (Bet), or the calcipotriol and betamethasone dipropionate 2-compound formulation (CB) was applied to 3 different psoriatic plaques with similar severity once a day for 14 days...
August 2016: Journal of Allergy and Clinical Immunology
J G Schlager, S Rosumeck, R N Werner, A Jacobs, J Schmitt, C Schlager, A Nast
People with chronic plaque psoriasis often have lesions on the scalp that are difficult to treat. This is a summary of a Cochrane review on efficacy and safety of topical treatments for scalp psoriasis. For quality of evidence assessment, we used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach. Only randomised controlled trials (RCTs) were eligible for inclusion. We searched the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, EMBASE and LILACS, ongoing trials, index of included studies and screened abstracts of six psoriasis-specific conferences up to August 2015...
June 17, 2016: British Journal of Dermatology
C Queille-Roussel, B Bang, F Clonier, J-P Lacour
BACKGROUND: An aerosol foam formulation of fixed combination calcipotriol 50 μg/g (Cal) and betamethasone 0.5 mg/g (as dipropionate; BD) has been developed for psoriasis vulgaris treatment. OBJECTIVE: To compare Cal/BD aerosol foam pharmacodynamic activity with Cal/BD ointment and with other topical corticosteroids of different potencies by assessing vasoconstrictor potential. METHODS: A Phase I, single-centre, investigator-blinded, vehicle-controlled, intra-individual comparison vasoconstriction study...
June 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
George Kontochristopoulos, Anargyros Kouris, Athanasios Chantzaras, Athanasios Petridis, John Yfantopoulos
BACKGROUND: Psoriasis is a common, chronic, recurrent, immune-mediated disorder of the skin and joints. It can have a significant negative impact on the physical, emotional and psychosocial wellbeing of affected patients. OBJECTIVES: To measure improvement in health-related QoL (HRQoL) in Greek patients with psoriasis vulgaris after a month of treatment with calcipotriol-betamethasone dipropionate gel; and evaluate adherence to treatment parameters. METHODS: The study included 394 psoriasis vulgaris patients from 16 private dermatological practices in Greece, all treated with calcipotriol-betamethasone dipropionate gel...
April 2016: Anais Brasileiros de Dermatologia
Lars Iversen, Henny B Jakobsen
INTRODUCTION: Topicals are a mainstay in psoriasis vulgaris treatment and are used concomitantly even in patients receiving systemic therapy. Patient acceptance of topical treatment can impact adherence and, consequently, real-life effectiveness. This study aimed to identify patient preferences for topical treatment attributes and to evaluate patient acceptability of topical treatments. METHODS: This 5-day study evaluated three inactive presentations: fixed combination calcipotriol/betamethasone dipropionate (Cal/BD) ointment vehicle in a tube, Cal/BD gel vehicle in a bottle and Cal/BD gel vehicle in a new Applicator delivery system...
June 2016: Dermatology and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"